Abstract
The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
Keywords: Ran GTPase, Ranbp1, Ranbp2, Ranbp9, Ranbp10, c-met, nucleo-cytoplasmic transport, macromolecules, anthologies, mitosis, cancer, oncogenic pathway, metastasis, microtubule-interacting drugs, chemotherapy
Current Molecular Medicine
Title: RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Volume: 11 Issue: 8
Author(s): K. J. Doherty, C. McKay, K. K. Chan and M. K. El-Tanani
Affiliation:
Keywords: Ran GTPase, Ranbp1, Ranbp2, Ranbp9, Ranbp10, c-met, nucleo-cytoplasmic transport, macromolecules, anthologies, mitosis, cancer, oncogenic pathway, metastasis, microtubule-interacting drugs, chemotherapy
Abstract: The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
Export Options
About this article
Cite this article as:
J. Doherty K., McKay C., K. Chan K. and K. El-Tanani M., RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins, Current Molecular Medicine 2011; 11 (8) . https://dx.doi.org/10.2174/156652411797536688
DOI https://dx.doi.org/10.2174/156652411797536688 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Structural Aspects of Crystalline Derivatized Cyclodextrins and Their Inclusion Complexes
Current Organic Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry MicroRNAs as Therapeutic Targets for Anticancer Drugs in Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs and Bone Regeneration
Current Genomics New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry The Molecular Mechanism of <i>Scutellaria baicalensis</i> Georgi Stems and Leaves Flavonoids in Promoting Neurogenesis and Improving Memory Impairment by the PI3K-AKT-CREB Signaling Pathway in Rats
Combinatorial Chemistry & High Throughput Screening Role of Apoptosis and Apoptosis-Related Genes in Cellular Response and Antitumor Efficacy of Anthracyclines
Current Medicinal Chemistry Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets The mAP-KL Algorithm Combined with Mutual Information Network Used to Screen Hub Genes in Osteosarcoma
Current Bioinformatics Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer
Current Immunology Reviews (Discontinued)